Published in Cancer Weekly, October 11th, 2011
"While initial reports were very promising, more recent results looking specifically at pulmonary lesions with low levels of FDG avidity demonstrated limitations. These lesions (initial maximum standard uptake value of less than 2.5) are of particular...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2011-10-11)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.